Found 126 clinical trials
Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer
PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease. The
- 0 views
- 04 Oct, 2022
- 1 location
The Modulatory Role of Internet MBCT on Extracellular Vesicles and Distress in Cancer Patients - Study Protocol (MINDGAP)
), interferon gamma (IFN-γ), tumour necrosis factor (TNF), and c-reactive protein (CRP); telomerase activity; antigens related to cancer (cancer antigen - CA 15-3; prostate-specific antigen - PSA
- 0 views
- 13 Sep, 2023
- 1 location
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s) (ProsTone)
even at very low PSA (prostate-specific Antigen) values. This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national
- 0 views
- 26 May, 2022
- 1 location
Phase II Study of Single-Dose Image-Guided Radiotherapy (SDRT) for Prostate Cancer (PROSINT II)
classified according to the current National Comprehensive Cancer Network (NCCN) guidelines as low or intermediate risk (biopsy Gleason score of 7 and/or Prostate Specific Antigen (PSA) level 20 ng/mL and/or
- 4 views
- 13 Feb, 2022
- 1 location
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
parts of the body yet keeps progressing despite low levels of (the hormone) testosterone. Signs of cancer progression are detected by higher (blood) levels of a protein known as "prostate-specific
- 0 views
- 12 Sep, 2023
- 1 location
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
castration-resistant metastatic disease. Localized disease is often classified according to a risk stratification system, which includes assessment of the Gleason score, prostate-specific antigen (PSA) at
- 0 views
- 14 Aug, 2023
- 1 location
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
. In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant). Prostate-specific antigen (PSA) is a protein that is made by both normal cells
- 0 views
- 18 Sep, 2023
- 10 locations
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer (BLAST)
This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.
- 0 views
- 04 Oct, 2022
- 1 location
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer (SOAR)
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Surgical procedures, such as oligometastasectomy, may remove …
- 0 views
- 25 Mar, 2022
- 1 location
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2)
This is a multicenter, randomized, open label, phase III study comparing the efficacy and safety of apatulamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) versus concomitant prostate-bed SRT and ADT in high-risk postprostatectomy biochemically relapsed prostate cancer patients.
- 7 views
- 25 Feb, 2022
- 6 locations